M 79175

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584776

CAS#: 82319-87-7

Description: M 79175 is an aldose reductase inhibitor.


Chemical Structure

img
M 79175
CAS# 82319-87-7

Theoretical Analysis

MedKoo Cat#: 584776
Name: M 79175
CAS#: 82319-87-7
Chemical Formula: C12H11FN2O3
Exact Mass: 250.0754
Molecular Weight: 250.2294
Elemental Analysis: C, 57.60; H, 4.43; F, 7.59; N, 11.20; O, 19.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: M 79175; E-1008

IUPAC/Chemical Name: Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione, 6-fluoro-2,3-dihydro-2-methyl-

InChi Key: SEAQTHCVAGBRFY-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11FN2O3/c1-6-5-12(10(16)14-11(17)15-12)8-4-7(13)2-3-9(8)18-6/h2-4,6H,5H2,1H3,(H2,14,15,16,17)

SMILES Code: O=C1NC2(C(N1)=O)CC(C)OC3=CC=C(F)C=C23

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 250.2294 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kador PF, Wyman M, Oates PJ. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®). Prog Retin Eye Res. 2016 Sep;54:1-29. doi: 10.1016/j.preteyeres.2016.04.006. Epub 2016 Apr 19. Review. PubMed PMID: 27102270.

2: Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985 Jul;28(7):841-9. Review. PubMed PMID: 3925146.

3: Kato A, Horie T, Ishibashi Y, Miyake Y, Iwata S. Corneal permeability of aldose reductase inhibitor, M79175. II. In vivo study on pharmacokinetic aspect. J Ocul Pharmacol. 1986 Summer;2(3):287-94. PubMed PMID: 3139809.

4: Sato S, Takahashi Y, Wyman M, Kador PF. Progression of sugar cataract in the dog. Invest Ophthalmol Vis Sci. 1991 May;32(6):1925-31. PubMed PMID: 1903366.

5: Hotta N, Sakamoto N. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]. Nihon Rinsho. 1987 Dec;45(12):3010-27. Review. Japanese. PubMed PMID: 3128677.

6: Kador PF, Akagi Y, Terubayashi H, Wyman M, Kinoshita JH. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1988 Aug;106(8):1099-102. PubMed PMID: 3401138.

7: Sato S, Mori K, Wyman M, Kador PF. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Exp Eye Res. 1998 Feb;66(2):217-22. PubMed PMID: 9533847.

8: Cusick M, Chew EY, Ferris F 3rd, Cox TA, Chan CC, Kador PF. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch Ophthalmol. 2003 Dec;121(12):1745-51. PubMed PMID: 14662595.

9: Neuenschwander H, Takahashi Y, Kador PF. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther. 1997 Dec;13(6):517-28. PubMed PMID: 9436155.

10: Wada E. r-Galactonolactone in experimental galactosemic animals. Arch Biochem Biophys. 1986 Nov 15;251(1):215-21. PubMed PMID: 3098177.

11: Poulsom R. Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type. Biochem Pharmacol. 1987 May 15;36(10):1577-81. PubMed PMID: 3109423.

12: Poulsom R. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate. Biochem Pharmacol. 1986 Sep 1;35(17):2955-9. PubMed PMID: 3091036.

13: Kador PF, Takahashi Y, Sato S, Wyman M. Amelioration of diabetes-like retinal changes in galactose-fed dogs. Prev Med. 1994 Sep;23(5):717-21. PubMed PMID: 7845946.

14: Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr;23(2):116-23. PubMed PMID: 17444799.

15: Ashizawa K, Uchikawa K, Hattori T, Sato T, Miyake Y. Polymorphic differences in alpha- and beta-form crystals of 2R, 4S, 6-fluoro-2-methyl-spiro[chroman-4,4'-imidazoline]-2',5-dione (M79175) as determined by X-ray diffraction, infrared spectroscopy, and differential scanning calorimetry. J Pharm Sci. 1988 Jul;77(7):635-7. PubMed PMID: 3171953.

16: Horie T, Kitada M, Yoshioka H, Kanakubo Y, Omura T. 6-Fluoro-2-methylspiro(chroman-4,4'-imidazolidine)-2',5'-dione and related compounds as inducers of monooxygenase in rat liver microsomes. Drug Metab Dispos. 1987 Jul-Aug;15(4):560-4. PubMed PMID: 2888631.

17: Funada M, Okamoto I, Fujinaga Y, Yamana T. Effects of aldose reductase inhibitor (M79175) on ERG oscillatory potential abnormalities in streptozotocin fructose-induced diabetes in rats. Jpn J Ophthalmol. 1987;31(2):305-14. PubMed PMID: 3118085.

18: Teshima R, Taura T, Okamura R. Inhibition of in utero galactose-induced cataract development by an aldose reductase inhibitor in rat--electron microscopic study. Jpn J Ophthalmol. 1993;37(2):192-8. PubMed PMID: 8230845.

19: Ashizawa K. Polymorphism and crystal structure of 2R,4S,6-fluoro-2-methyl-spiro[chroman-4,4'-imidazoline]-2',5-dione (M79175). J Pharm Sci. 1989 Mar;78(3):256-60. PubMed PMID: 2724085.

20: Akagi Y, Kador PF. Effect of aldose reductase inhibitors on the progression of retinopathy in galactose-fed dogs. Exp Eye Res. 1990 Jun;50(6):635-9. PubMed PMID: 2115453.